ABSTRACT
Objectives Hearing loss is most commonly observed at high frequencies. High-frequency hearing loss (HFHL) precedes and predicts hearing loss at lower frequencies. It was previously shown that an automated, self-administered digits-in-noise (DIN) test can be sensitized for detection of HFHL by low-pass filtering the speech-shaped masking noise at 1.5 kHz. This study was designed to investigate whether sensitivity of the DIN to HFHL can be enhanced further using low-pass noise filters with higher cutoff frequencies.
Design US-English digits 0-9, homogenized for audibility, were binaurally presented in different noise maskers including one broadband and three low-pass (cut-off at 2, 4, 8 kHz) filtered speech-shaped noises. DIN-Speech reception thresholds (SRTs) were obtained from 60 normal hearing (NH), and 40 mildly hearing impaired (HI) listeners with bilateral symmetric sensorineural hearing-loss. Standard and extended high frequency audiometric pure tone averages (PTAs) were compared with the DIN-SRTs.
Results Narrower masking noise bandwidth generally produced better (more sensitive) mean DIN-SRTs. There were strong and significant correlations between SRT and PTA in the HI group. Lower frequency, PTALF 0.5,1, 2, 4 kHz had the highest correlation and steepest slope with SRTs obtained from the 2 kHz filter. Higher frequency, PTAHF 4,8,10,12.5 kHz correlated best with SRTs obtained from 4 and 8 kHz filtered noise. The 4 kHz low-pass filter also had the highest sensitivity (92%) and equally-highest (with the 8 kHz filter) specificity (90%) for detecting an average PTAHF of 20 dB or more.
Conclusions Of the filters used, DIN sensitivity to higher frequency hearing loss was greatest using the 4 kHz low-pass filter. These results suggest that low-pass filtered noise may be usefully substituted for broadband noise to improve earlier detection of HFHL using DIN.
Competing Interest Statement
De Wet Swanepoel is co-founder, lead inventor and shareholder, and David Moore is a scientific advisor and shareholder of the hearX Group. No author has any other financial or non-financial interest in relation to the work described.
Funding Statement
This study was supported by NIH grant R21DC016241 and by the Cincinnati Childrens Hospital Research Foundation. David Moore receives support from the NIHR Manchester Biomedical Research Center.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Cincinnati Children's Hospital-IRB Number: 2018-0180
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the corresponding author.
